Red Group’s Post

This morning the UK regulator, the MHRA, has approved new drug donanemab to treat mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. However, draft guidance released simultaneously by NICE says more evidence is needed on the clinical and cost-effectiveness of the drug, therefore it wont be available on the NHS. Draft guidance by NICE states that the costs of providing donanemab, including the monthly infusions and intensive monitoring for serious side effects, balanced against the relatively small benefit it provides to patients, means it cannot currently be considered good value for the taxpayer. UK DRI Director Prof Siddharthan Chandran said: “These first drugs are just the opening chapter for Alzheimer’s treatments. Today’s MHRA approval of donanemab is another step towards a future where we can begin to offer treatments to people affected by dementia. In this case, NICE’s initial recommendation is that the benefits of the drug are not significant enough to make it cost effective, which means it will not be available to patients on the NHS. This will be disappointing to many. However, I do believe we are at a pivotal moment in our research mission to develop better, safer treatments." UK DRI scientists respond to the news ⬇️

NICE has released draft guidance recommending that Donanemab should not be funded for treating mild Alzheimer's disease in the NHS. While this first-in-class therapy shows early evidence of slowing cognitive decline, the high cost and uncertainties around long-term benefits mean it does not meet NICE's cost-effectiveness criteria. The committee considered a recommendation for managed access, but concluded the proposed plan was unlikely to address evidence uncertainties significantly given no NHS-level data collection. They would welcome a revised managed access proposal from the sponsor. This decision highlights the challenges in balancing innovation with affordability, particularly in diseases like Alzheimer's where treatment needs are urgent but options remain limited. What steps can be taken to properly address long-term evidence uncertainties in chronic conditions, while also avoiding delays in access to potentially disease-modifying treatments? #Alzheimers #AlzheimersTreatment #DementiaCare #NHS #HTA #HealthEconomics #DrugDevelopment #Pharmaceuticals

https://lnkd.in/eFPPKNqq Good news was announced on this morning's 'Today' program on Radio 4. A new treatment for the management of symptoms of Parkinson's will now be made available through the NHS in England. The drug has recently been approved for NHS use by the National Institute for Health and Care Excellence (NICE) after successful clinical trials. It is thought that at least 1,000 People living with Parkinson's in England will benefit. I am absolutely over the moon that more people living with Parkinson's now potentially may benefit from this treatment because as a trial participant since December 2019, I can only say: it has been 'transformational'. The NICE guidance can be found here https://lnkd.in/eFPPKNqq In Scotland the approval process consists of an application to the Scottish Medicines Consortium (SMC) and, if recommended for use, consideration by the local Area Drug and Therapeutic Committees (ADTCs) of the NHS boards. ADTCs decide whether to include a medicine in their prescribing guidance. I have every finger crossed, almost like causing oneselves dystonia, hoping that the SMC and ADTC's will include the treatment in their prescribing guidance. #parkinsons, #ParkinsonUK, #CureParkinsons #DundeePPU #DRIG #UniversityofDunddee, #Abbvie, #EUPATI, #PFMD, #MJF, #PDAvenegers

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare

The efficacy of GLP-1 medications in managing type 2 #diabetes is well-established in medical literature and clinical practice guidelines. There's less robust support for the widespread use of pharmacotherapy in the treatment of #obesity as a standard of care, although, as with other chronic diseases, some patients may benefit from medications. We explain how to manage your priorities around Rx #benefits, especially GLP-1s. #healthcare